Eric Pauwels compensation by year
PTC THERAPEUTICS Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $570,217 | $613,150 |
| Bonus | $0 | $0 |
| Stock awards | $624,267 | $1,023,880 |
| Option awards | $742,031 | $1,382,782 |
| Non-equity incentive | $0 | $517,800 |
| Pension and deferred compensation | $436,900 | $0 |
| All other | $25,056 | $25,356 |
| Total | $2,398,470 | $3,562,968 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PTC THERAPEUTICS, INC. DEF 14A filed April 20, 2026, accession 0001104659-26-045528, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 22,000 | $1,671,120 | — |
| RSU | 16,500 | $1,253,340 | — |
| RSU | 9,000 | $683,640 | — |
| RSU | 4,200 | $319,032 | — |
| RSU | 1,150 | $87,354 | — |
| Option | 55,000 | — | $46.54 |
| Option | 3,938 | — | $38.10 |
| Option | 14,063 | — | $39.42 |
| Option | 30,938 | — | $25.69 |
Per the Outstanding Equity Awards at Fiscal Year-End table in PTC THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2025 proxy (filed April 20, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-10 | Exercise or conversion | 10b5-1 | 17,566 | $18.01 | 90,977 |
| 2026-06-10 | Sale | 10b5-1 | 3,711 | $75.00 | 73,411 |
| 2026-06-10 | Sale | 10b5-1 | 17,566 | $75.00 | 73,411 |
| 2026-06-10 | Sale derivative | 10b5-1 | 17,566 | $0.00 | 0 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments PTC THERAPEUTICS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $621,000 | $0 | $46,924 | $667,924 |
| Change in control and involuntary termination | $931,500 | $7,850,794 | $46,924 | $8,829,218 |
Per the Potential Payments Upon Termination or Change in Control table in PTC THERAPEUTICS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
PTC THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Matthew Klein | Chief Executive Officer | $23,266,326 |
| Eric Pauwels · this page | Chief Business Officer | $3,562,968 |
| Pierre Gravier | Chief Financial Officer | $3,550,786 |
| Lee Golden | Executive Vice President and Chief Medical Officer | $3,269,179 |
| Neil Almstead | Chief Technical Operations Officer | $3,159,055 |
The full PTC THERAPEUTICS compensation record
free company briefThis page is one person within PTC THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order PTC THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PTC THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat